SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Techniclone (TCLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JOHN ASHBOLT who wrote (3168)6/21/1999 7:14:00 PM
From: Terry D.  Read Replies (1) of 3702
 
From UCLA site

Treatment of Newly Diagnosed or Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme. HSPC# 98-10-047-01A For more information, please call (310)794-7542
The purpose of this study is to take advantage of the knowledge gained in the phase I study and in the fields of immunology (study of immunity) and antibody therapy to study treatments of newly diagnosed and recurrent brain tumors. This phase II experimental treatment will be combined with non-experimental surgical removal of the tumor as planned by the doctor. Special proteins called antibodies that are combined with a form of radioactive iodine (131I) will be injected into a catheter (small tubing) in my brain. This antibody is designed to attach to a protein in the tumor. The combination of the antibody and radioactive iodine is called 131I-chTNT-1/B. Combined with the radioactive iodine, this medication can lead to destruction of the tumor cell by providing radiation within the brain. Injection of the study medication into the intratumoral (inside the tumor)space (called interstitial therapy) reduces radiation exposure to other areas of the body. The purpose of this research study is:

1. Determine the safety and efficacy of the research medication 131I-chTNT-1/B in the treatment of brain cancer (newly diagnosed or recurrent Anaplastic Astrocytoma type of Glioblastoma Multiforme
type brain tumor); and
2. To assess the impact of re-treatment on stopping tumor reoccurrence.
This study has been designed for two groups of patients. One with newly diagnosed and the other with recurrent anaplastic astrocytoma and glioblastoma multiforms who are going to have surgery to remove their tumor. A surgical removal of the tumor or biopsy must be done 5-15 days before the patient can be eligible for treatment. The study medication will be given to the patient after the doctor has removed as much of the tumor as possible. Patients will receive a single infusion of 131I by a catheter into their brain. Side effects will be
evaluated. A MRI will be performed within seven days of planned catheter placement to define the pre-surgical tumor.
This study treatment is intended for patients who have newly diagnosed or recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme.

neurooncology.ucla.edu
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News